UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 102

Sortiert nach

Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program

Pediatric blood & cancer, 2016-10, Vol.63 (10), p.1744-1752

2016

Volltextzugriff (PDF)

Correction: Reversing the Warburg effect as a treatment for glioblastoma

The Journal of biological chemistry, 2018-09, Vol.293 (39), p.14973-14973

2018

Volltextzugriff (PDF)

Levels of stress and intervention preferences of caregivers of brain tumor patients

Cancer nursing, 2007-11, Vol.30 (6), p.E33

Keir, Stephen T

2007

Volltextzugriff (PDF)

IDENTIFICATION AND PRELIMINARY TREATMENT DATA OF XENOGRAFTS REPRESENTING TCGA-DEFINED SUBTYPES

Neuro-oncology (Charlottesville, Va.), 2014-07, Vol.16 (suppl 3), p.iii35-iii35

2014

Volltextzugriff (PDF)

PATIENT-DERIVED XENOGRAFTS MIRROR THE PROTEOMIC PROFILE OF HUMAN GLIOBLASTOMA: IMPLICATIONS FOR PERSONALIZED DRUG DEVELOPMENT

Neuro-oncology (Charlottesville, Va.), 2014-07, Vol.16 (suppl 3), p.iii38-iii38

2014

Volltextzugriff (PDF)

The emerging role of irinotecan (CPT‐11) in the treatment of malignant glioma in brain tumors

Cancer, 2003-05, Vol.97 (S9), p.2359-2362

2003

Volltextzugriff (PDF)

Distress persists in long-term brain tumor survivors with glioblastoma multiforme

Journal of cancer survivorship, 2008-12, Vol.2 (4), p.269-274

2008

Volltextzugriff (PDF)

DNAR-08. THE ROLE OF SMARCAL1 AS A SYNTHETIC LETHAL VULNERABILITY IN ATRX-DEFICIENT GLIOMAS

Neuro-oncology (Charlottesville, Va.), 2022-11, Vol.24 (Supplement_7), p.vii91-vii92

2022

Volltextzugriff (PDF)

Program preferences to reduce stress in caregivers of patients with brain tumors

Clinical journal of oncology nursing, 2007-10, Vol.11 (5), p.723

2007

Volltextzugriff (PDF)

Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis: Laboratory investigation

Journal of neurosurgery, 2013-12, Vol.119 (6), p.1415-1423

2013

Volltextzugriff (PDF)

LGG-01. EVALUATION OF COBIMETINIB, A MEK INHIBITOR, IN LOW-GRADE PEDIATRIC BRAIN TUMORS

Neuro-oncology (Charlottesville, Va.), 2018-06, Vol.20 (suppl_2), p.i104-i105

2018

Volltextzugriff (PDF)

TMOD-27. EFFICACY OF SOLUBLE PANOBINOSTAT (MTX110) IN PRECLINICAL MODELS OF ADULT GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Supplement_2), p.ii233-ii233

2020

Volltextzugriff (PDF)

EXTH-57. EFFICACY OF SOLUBLE PANOBINOSTAT (MTX110) IN PRECLINICAL MODELS OF ADULT GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi176-vi176

2021

Volltextzugriff (PDF)

Abstract 5821: The role of SMARCAL1 loss-of-function mutations in glioblastoma telomere maintenance

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5821-5821

2020

Volltextzugriff (PDF)

TMOD-33. ESTABLISHMENT AND PRELIMINARY EVALUATION OF BEVACIZUMAB-RESISTANT GLIOMA XENOGRAFT MODELS

Neuro-oncology (Charlottesville, Va.), 2018-11, Vol.20 (suppl_6), p.vi275-vi275

2018

Volltextzugriff (PDF)

Immunotoxin and bcl-2 inhibitor combination therapy targeting chondroitin sulfate proteoglycan 4

Journal of clinical oncology, 2017-03, Vol.35 (7_suppl), p.74-74

2017

Volltextzugriff (PDF)

A combinatorial immunotherapy for malignant brain tumors: D2C7 immunotoxin and immune checkpoint inhibitors

Journal of clinical oncology, 2017-03, Vol.35 (7_suppl), p.102-102

2017

Volltextzugriff (PDF)

A phase 0/surgical window-of-opportunity study in progress, evaluating evolocumab in patients with high-grade glioma or glioblastoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS2076-TPS2076

2022

Volltextzugriff (PDF)

IMMU-34. ATRX MUTATIONS PREDICT RESPONSE TO INNATE BASED THERAPY IN GLIOMA

Neuro-oncology (Charlottesville, Va.), 2019-11, Vol.21 (Supplement_6), p.vi126-vi126

2019

Volltextzugriff (PDF)

A Modified Nucleoside 6-thio-2’-deoxyguanosine Exhibits Anti-tumor Activity in Gliomas

Clinical cancer research, 2021-09, Vol.27 (24), p.6800-6814

2021

Volltextzugriff (PDF)

IMMU-18. INTERPLAY BETWEEN IDH1 AND ATRX MUTATIONS GOVERN INNATE IMMUNE RESPONSES IN GLIOMAS

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Supplement_2), p.ii108-ii108

2020

Volltextzugriff (PDF)

ET-28COMBINATION THERAPY WITH MET TYROSINE KINASE INHIBITOR EMD1214063 AND BEVACIZUMAB

Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (Suppl 5), p.v85-v85

2014

Volltextzugriff (PDF)

BSCI-20 STING EPIGENETIC SILENCING IN GLIOMAS CAN BE RESCUED BY METHYLTRANSFERASE INHIBITION: IMPLICATIONS FOR NOVEL THERAPEUTIC APPROACHES

Neuro-oncology advances, 2022-08, Vol.4 (Supplement_1), p.i5-i5

2022

Volltextzugriff (PDF)

Abstract LB-76: Mibefradil, a novel therapy for glioblastoma: An interlaced therapy approach

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.LB-76-LB-76

2012

Volltextzugriff (PDF)

Abstract 4924: Alternative lengthening of telomeres is associated with hypersensitivity to topoisomerase 1 inhibition in glioblastoma xenograft models

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.4924-4924

2023

Volltextzugriff (PDF)

1 – 25 von 102

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieCancer Chemotherapy And Pharmacology

ThemaBalance Of Power

ThemaMice, Nude

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(91)
Mit Volltextzugriff
(90)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program

Correction: Reversing the Warburg effect as a treatment for glioblastoma

Levels of stress and intervention preferences of caregivers of brain tumor patients

IDENTIFICATION AND PRELIMINARY TREATMENT DATA OF XENOGRAFTS REPRESENTING TCGA-DEFINED SUBTYPES

PATIENT-DERIVED XENOGRAFTS MIRROR THE PROTEOMIC PROFILE OF HUMAN GLIOBLASTOMA: IMPLICATIONS FOR PERSONALIZED DRUG DEVELOPMENT

The emerging role of irinotecan (CPT‐11) in the treatment of malignant glioma in brain tumors

Distress persists in long-term brain tumor survivors with glioblastoma multiforme

DNAR-08. THE ROLE OF SMARCAL1 AS A SYNTHETIC LETHAL VULNERABILITY IN ATRX-DEFICIENT GLIOMAS

Program preferences to reduce stress in caregivers of patients with brain tumors

Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis: Laboratory investigation

LGG-01. EVALUATION OF COBIMETINIB, A MEK INHIBITOR, IN LOW-GRADE PEDIATRIC BRAIN TUMORS

TMOD-27. EFFICACY OF SOLUBLE PANOBINOSTAT (MTX110) IN PRECLINICAL MODELS OF ADULT GLIOBLASTOMA

EXTH-57. EFFICACY OF SOLUBLE PANOBINOSTAT (MTX110) IN PRECLINICAL MODELS OF ADULT GLIOBLASTOMA

Abstract 5821: The role of SMARCAL1 loss-of-function mutations in glioblastoma telomere maintenance

TMOD-33. ESTABLISHMENT AND PRELIMINARY EVALUATION OF BEVACIZUMAB-RESISTANT GLIOMA XENOGRAFT MODELS

Immunotoxin and bcl-2 inhibitor combination therapy targeting chondroitin sulfate proteoglycan 4

A combinatorial immunotherapy for malignant brain tumors: D2C7 immunotoxin and immune checkpoint inhibitors

A phase 0/surgical window-of-opportunity study in progress, evaluating evolocumab in patients with high-grade glioma or glioblastoma

IMMU-34. ATRX MUTATIONS PREDICT RESPONSE TO INNATE BASED THERAPY IN GLIOMA

A Modified Nucleoside 6-thio-2’-deoxyguanosine Exhibits Anti-tumor Activity in Gliomas

IMMU-18. INTERPLAY BETWEEN IDH1 AND ATRX MUTATIONS GOVERN INNATE IMMUNE RESPONSES IN GLIOMAS

ET-28COMBINATION THERAPY WITH MET TYROSINE KINASE INHIBITOR EMD1214063 AND BEVACIZUMAB

BSCI-20 STING EPIGENETIC SILENCING IN GLIOMAS CAN BE RESCUED BY METHYLTRANSFERASE INHIBITION: IMPLICATIONS FOR NOVEL THERAPEUTIC APPROACHES

Abstract LB-76: Mibefradil, a novel therapy for glioblastoma: An interlaced therapy approach

Abstract 4924: Alternative lengthening of telomeres is associated with hypersensitivity to topoisomerase 1 inhibition in glioblastoma xenograft models

Aktive Filter

Suchergebnisse filtern